JPWO2020114480A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020114480A5 JPWO2020114480A5 JP2021532180A JP2021532180A JPWO2020114480A5 JP WO2020114480 A5 JPWO2020114480 A5 JP WO2020114480A5 JP 2021532180 A JP2021532180 A JP 2021532180A JP 2021532180 A JP2021532180 A JP 2021532180A JP WO2020114480 A5 JPWO2020114480 A5 JP WO2020114480A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- region
- amino acid
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 230000035772 mutation Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 2
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 2
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 2
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 2
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/119797 | 2018-12-07 | ||
| CNPCT/CN2018/119797 | 2018-12-07 | ||
| PCT/CN2019/123588 WO2020114480A1 (en) | 2018-12-07 | 2019-12-06 | Anti-claudin antibodies and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022512132A JP2022512132A (ja) | 2022-02-02 |
| JP2022512132A5 JP2022512132A5 (https=) | 2022-12-13 |
| JPWO2020114480A5 true JPWO2020114480A5 (https=) | 2022-12-13 |
| JP7458399B2 JP7458399B2 (ja) | 2024-03-29 |
Family
ID=70975310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532180A Active JP7458399B2 (ja) | 2018-12-07 | 2019-12-06 | 抗クローディン抗体及びそれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210380680A1 (https=) |
| EP (1) | EP3891183A4 (https=) |
| JP (1) | JP7458399B2 (https=) |
| KR (1) | KR20210100655A (https=) |
| CN (1) | CN113423735B (https=) |
| AU (1) | AU2019391204A1 (https=) |
| BR (1) | BR112021011014A2 (https=) |
| CA (1) | CA3122135A1 (https=) |
| IL (1) | IL283754A (https=) |
| MX (1) | MX2021006681A (https=) |
| SG (1) | SG11202105885WA (https=) |
| WO (1) | WO2020114480A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12297265B2 (en) | 2018-12-28 | 2025-05-13 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Antibody and use thereof |
| CA3128502A1 (en) | 2019-02-01 | 2020-08-06 | Novarock Biotherapeutics, Ltd. | Anti-claudin 18 antibodies and methods of use thereof |
| CN115943162A (zh) * | 2020-06-19 | 2023-04-07 | 信达生物制药(苏州)有限公司 | 抗Claudin18.2抗体以及其用途 |
| CN113929780A (zh) * | 2020-07-13 | 2022-01-14 | 北京凯因科技股份有限公司 | 一种结合密蛋白的用于治疗癌症的人源化抗体 |
| KR20230079096A (ko) * | 2020-09-30 | 2023-06-05 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 항체-약물 접합체를 포함하는 약제학적 조성물 및 약제학적 조성물의 용도 |
| US20240034784A1 (en) * | 2020-09-30 | 2024-02-01 | Nanjing GenScript Biotech Co., Ltd. | Antibodies targeting human claudin 18.2 and uses thereof |
| CN115109154A (zh) * | 2021-03-17 | 2022-09-27 | 三优生物医药(上海)有限公司 | 一种靶向cldn18.2的抗体或其抗原结合片段及其应用 |
| CN115611983A (zh) * | 2021-07-14 | 2023-01-17 | 三优生物医药(上海)有限公司 | Cldn18.2结合分子及其用途 |
| WO2023066267A1 (en) * | 2021-10-19 | 2023-04-27 | Biosion Inc. | Antibodies binding cldn18.2 and uses thereof |
| CN114044822B (zh) * | 2021-10-28 | 2023-06-27 | 杭州博茵生物技术有限公司 | 血清淀粉样蛋白a抗体的重链和轻链可变区、抗体及运用 |
| CN118139888A (zh) * | 2021-11-05 | 2024-06-04 | 正大天晴药业集团股份有限公司 | 抗cldn18.2抗体及其用途 |
| CN114395040B (zh) * | 2022-02-09 | 2023-12-15 | 东南大学附属中大医院 | 再生蛋白reg1a单克隆抗体及其应用 |
| WO2023196882A1 (en) | 2022-04-06 | 2023-10-12 | Zai Lab (Us) Llc | Claudin 18.2 immunohistochemistry assay and use thereof |
| CN117229398A (zh) * | 2022-06-15 | 2023-12-15 | 中山康方生物医药有限公司 | 抗cldn18.2抗体、其药物组合物及用途 |
| CA3261520A1 (en) * | 2022-07-08 | 2024-01-11 | Telix Targeting Technologies, Inc. | ANTIBODIES, THEIR MANUFACTURING PROCESSES AND METHODS OF USE |
| WO2024131683A1 (zh) * | 2022-12-19 | 2024-06-27 | 华润生物医药有限公司 | 结合cldn18.2的抗体和抗体药物偶联物及其用途 |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004024617A1 (de) * | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| WO2013167153A1 (en) * | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014146672A1 (en) * | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| AU2017294276B2 (en) * | 2016-07-08 | 2024-08-01 | Crage Medical Co., Limited | Antibody for anti-claudin 18A2 and use thereof |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
-
2019
- 2019-12-06 JP JP2021532180A patent/JP7458399B2/ja active Active
- 2019-12-06 WO PCT/CN2019/123588 patent/WO2020114480A1/en not_active Ceased
- 2019-12-06 MX MX2021006681A patent/MX2021006681A/es unknown
- 2019-12-06 SG SG11202105885WA patent/SG11202105885WA/en unknown
- 2019-12-06 CN CN201980088317.6A patent/CN113423735B/zh active Active
- 2019-12-06 CA CA3122135A patent/CA3122135A1/en active Pending
- 2019-12-06 US US17/311,307 patent/US20210380680A1/en not_active Abandoned
- 2019-12-06 KR KR1020217020208A patent/KR20210100655A/ko not_active Ceased
- 2019-12-06 AU AU2019391204A patent/AU2019391204A1/en not_active Abandoned
- 2019-12-06 BR BR112021011014-3A patent/BR112021011014A2/pt not_active IP Right Cessation
- 2019-12-06 EP EP19893031.5A patent/EP3891183A4/en not_active Withdrawn
-
2021
- 2021-06-06 IL IL283754A patent/IL283754A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020114480A5 (https=) | ||
| JP2020508655A5 (https=) | ||
| JP2020073504A5 (https=) | ||
| JP2021503455A5 (https=) | ||
| JP2017149720A5 (https=) | ||
| GB2581620A (en) | GPCR binding proteins and synthesis thereof | |
| JP2018522888A5 (https=) | ||
| JP2018516853A5 (https=) | ||
| JP2009225799A5 (https=) | ||
| JP2012519492A5 (https=) | ||
| JP2024001073A5 (https=) | ||
| JP2017519759A5 (https=) | ||
| RU2021111382A (ru) | Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5 | |
| JP2021520832A5 (https=) | ||
| JP2021530244A5 (https=) | ||
| JP2021512604A5 (https=) | ||
| IL280487B2 (en) | Anti-mica/b antibodies that block mica/b shedding and methods of use | |
| JP2020522488A5 (https=) | ||
| JP2021511387A5 (https=) | ||
| CN115461373A (zh) | 密蛋白18.2的抗体及其用途 | |
| JP2022500455A5 (https=) | ||
| JP2021529524A5 (https=) | ||
| CN114829405B (zh) | 抗bcma/抗4-1bb双特异性抗体及其用途 | |
| JP2018513141A5 (https=) | ||
| JPWO2022111425A5 (https=) |